{
    "clinical_study": {
        "@rank": "21656", 
        "arm_group": [
            {
                "arm_group_label": "MK-0476 OG/1-5 year olds/4 or 12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants aged 1 to 5 years old receiving MK-0476 OG for 4 or 12 weeks"
            }, 
            {
                "arm_group_label": "MK-0476 CT/6-9 year olds/12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants aged 6 to 9 years old receiving MK-0476 CT for 12 weeks"
            }, 
            {
                "arm_group_label": "MK-0476 CT/10-15 year olds/12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants aged 10 to 15 years old receiving MK-0476 CT for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and pharmacokinetics of MK-0476 in the treatment of\n      Japanese pediatric participants with perennial allergic rhinitis (PAR)."
        }, 
        "brief_title": "Study of the Safety and Pharmacokinetics of MK-0476 in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Perennial Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight \u2265 8 kg\n\n          -  Diagnosis of PAR and has symptoms of PAR at Visit 1\n\n        Exclusion Criteria:\n\n          -  Past or present medical history of asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852812", 
            "org_study_id": "0476-520"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-0476 OG/1-5 year olds/4 or 12 weeks", 
                "description": "MK-0476 4 mg OG, taken once daily at bed time for 4 or 12 weeks", 
                "intervention_name": "MK-0476 Oral Granules (OG)", 
                "intervention_type": "Drug", 
                "other_name": "montelukast sodium"
            }, 
            {
                "arm_group_label": [
                    "MK-0476 CT/6-9 year olds/12 weeks", 
                    "MK-0476 CT/10-15 year olds/12 weeks"
                ], 
                "description": "MK-0476 5 mg CT, taken once daily at bed time for 12 weeks", 
                "intervention_name": "MK-0476 Chewable Tablets (CT)", 
                "intervention_type": "Drug", 
                "other_name": "montelukast sodium"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Montelukast"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants Who Experience at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after last dose of study drug"
            }, 
            {
                "measure": "Area Under the Curve (AUC) of MK-0476 Chewable Tablets (CT) and MK-0476 Oral Granules (OG)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28 after first dose of study drug"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852812"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}